Breast Cancer

The investigational oral selective estrogen receptor degrader (SERD) elacestrant (RAD1901) significantly reduced the risk for death or disease progression and improved progression-free survival (PFS) compared with standard of care (SOC) endocrine therapy in patients with estrogen receptor (ER)-­positive, HER2-negative metastatic breast cancer who had progressed on previous endocrine and targeted therapies, according to results of the phase 3 EMERALD clinical trial. Read More ›

The COVID-19 pandemic continues to impact healthcare across the globe. Read More ›

The phase 3 OlympiA trial showed olaparib had impressive results versus placebo, with improvement in disease-free survival with adjuvant olaparib in early-stage, HER2-negative breast cancer and BRCA1/2 mutations. This highlights the need to test for BRCA1/2 mutations to determine if patients qualify for olaparib. Read More ›

A recent study found that omega-6 PUFA supplementation surprisingly reduced cancer-related fatigue in exhausted American breast cancer survivors when compared with omega-3 PUFA supplementation, and that omega-6 PUFA supplementation surprisingly lowered proinflammatory blood markers, completely against expectations. Read More ›

Results of a recent web-based survey show that survey respondents are in favor of several changes in breast cancer treatment during COVID-19. These changes must be discussed on a local level, taking into consideration the infrastructure and resources available. Read More ›

In a real-world study, more than 60% of the HR-positive, HER2-negative advanced breast cancer samples had ≥1 disease-related poor prognostic factors. The need for more effective CDK4/6 inhibitor medication in these individuals is highlighted by their increased pain and impaired performance status. Read More ›

Adding CDK4/6 inhibitors to fulvestrant resulted in an improvement in overall survival. These findings back up the current standard of care of CDK4/6 inhibitors plus fulvestrant for patients with HR-positive, HER2-negative, advanced breast cancer. Read More ›

PARP inhibitors offer the possibility of biomarker-targeted treatment for breast cancer. Therefore, it is necessary to quickly identify which patients may benefit from treatment and to guarantee that genetic testing is available. Read More ›

A real-world investigation has found that CDK4/6 inhibitor treatment outcomes are worse in patients with germline BRCA mutation–positive metastatic breast cancer than in patients with germline BRCA wild-type disease and unclear germline BRCA status, implying possible changes in tumor biology. Read More ›

Clinical studies have demonstrated that olaparib is clinically efficacious in patients with germline BRCA mutation–positive, HER2-negative metastatic breast cancer in a setting closely resembling the real world. Read More ›

Page 1 of 15

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: